Related Experiment Videos
A novel B-CLL specific nuclear protein (p44/46).
J Chruściel1, J Błonski, P Szymczyk
1Department of Cytobiochemistry, University of Lódź, Poland.
Leukemia Research
|September 4, 1999
Summary
Researchers identified a specific 44/46 kDa nuclear protein in B cell chronic lymphocytic leukemia (B-CLL) and acute lymphoblastic leukemia (ALL) cells. This protein, absent in healthy cells, may indicate disease progression.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- Protein expression profiles in mononuclear cells differ between B cell chronic lymphocytic leukemia (B-CLL) patients and healthy donors.
- Significant variations in nuclear protein electrophoretic patterns were noted, particularly between 37-52 kDa.
Purpose of the Study:
- To identify and characterize a specific nuclear protein antigen associated with B-CLL.
- To develop a diagnostic tool for B-CLL and related leukemias.
Main Methods:
- Electrophoresis was used to analyze protein fractions from mononuclear cells.
- Polyclonal antiserum was generated against a 44/46 kDa nuclear protein from B-CLL cells.
- Western blot analysis with alkaline phosphatase detected the target antigen.
Main Results:
- The generated antiserum specifically recognized a 44/46 kDa nuclear antigen in B-CLL and acute lymphoblastic leukemia (ALL) cells, but not in normal cells.
- No cross-reactivity was observed with T cell chronic lymphocytic leukemia (T-CLL) or non-leukemic tissues (stomach, colon).
- Higher expression of this antigen correlated with B-CLL progression.
Conclusions:
- A 44/46 kDa nuclear protein antigen is a potential biomarker for B-CLL and ALL.
- This antigen shows specificity for certain leukemic types and does not cross-react with normal tissues.
- The antigen's expression level may serve as an indicator of B-CLL disease progression.